| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contrast Media | 31 | 2025 | 507 | 5.400 |
Why?
|
| Nanoparticles | 20 | 2025 | 290 | 3.600 |
Why?
|
| Liposomes | 30 | 2019 | 202 | 2.760 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2025 | 3831 | 2.150 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2025 | 2169 | 1.830 |
Why?
|
| Placenta | 6 | 2025 | 538 | 1.820 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2022 | 152 | 1.490 |
Why?
|
| Drug Carriers | 12 | 2012 | 119 | 1.300 |
Why?
|
| Gadolinium | 7 | 2019 | 115 | 1.290 |
Why?
|
| Optical Imaging | 3 | 2018 | 72 | 1.220 |
Why?
|
| Indocyanine Green | 3 | 2023 | 63 | 1.150 |
Why?
|
| Fluorocarbons | 2 | 2018 | 58 | 1.100 |
Why?
|
| Computer-Aided Design | 2 | 2020 | 22 | 1.080 |
Why?
|
| Alzheimer Disease | 6 | 2024 | 854 | 1.070 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2021 | 377 | 1.020 |
Why?
|
| Models, Anatomic | 2 | 2020 | 104 | 1.020 |
Why?
|
| Triiodobenzoic Acids | 5 | 2021 | 31 | 0.980 |
Why?
|
| Drug Delivery Systems | 7 | 2012 | 223 | 0.970 |
Why?
|
| Ferrosoferric Oxide | 1 | 2025 | 27 | 0.880 |
Why?
|
| Phantoms, Imaging | 4 | 2018 | 133 | 0.820 |
Why?
|
| Animals | 51 | 2025 | 34798 | 0.800 |
Why?
|
| Placenta Accreta | 1 | 2025 | 169 | 0.750 |
Why?
|
| X-Ray Microtomography | 3 | 2021 | 95 | 0.740 |
Why?
|
| Angiography | 2 | 2021 | 208 | 0.730 |
Why?
|
| Plaque, Amyloid | 3 | 2020 | 68 | 0.730 |
Why?
|
| Mice | 29 | 2025 | 18466 | 0.710 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 2 | 2018 | 65 | 0.700 |
Why?
|
| Cerebrovascular Disorders | 1 | 2021 | 119 | 0.670 |
Why?
|
| Atherosclerosis | 2 | 2022 | 1008 | 0.640 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 68 | 0.630 |
Why?
|
| Medical Oncology | 2 | 2023 | 244 | 0.620 |
Why?
|
| Insulin | 3 | 2012 | 1168 | 0.610 |
Why?
|
| Computer Simulation | 2 | 2021 | 697 | 0.600 |
Why?
|
| Fluorine | 1 | 2018 | 15 | 0.590 |
Why?
|
| Amyloid | 2 | 2020 | 69 | 0.580 |
Why?
|
| Disease Models, Animal | 14 | 2022 | 4685 | 0.580 |
Why?
|
| Hindlimb | 1 | 2018 | 76 | 0.580 |
Why?
|
| Fluorine-19 Magnetic Resonance Imaging | 1 | 2018 | 4 | 0.570 |
Why?
|
| Integrin alpha4beta1 | 1 | 2018 | 27 | 0.560 |
Why?
|
| Ethers | 1 | 2018 | 9 | 0.560 |
Why?
|
| Neoplasms | 7 | 2023 | 2957 | 0.550 |
Why?
|
| Radiography, Thoracic | 3 | 2015 | 154 | 0.540 |
Why?
|
| Aortography | 2 | 2021 | 183 | 0.540 |
Why?
|
| Skull | 1 | 2018 | 143 | 0.530 |
Why?
|
| Immunotherapy | 3 | 2023 | 745 | 0.510 |
Why?
|
| Amyloid beta-Protein Precursor | 3 | 2020 | 133 | 0.510 |
Why?
|
| Blood-Brain Barrier | 2 | 2014 | 156 | 0.500 |
Why?
|
| Neuroblastoma | 2 | 2021 | 550 | 0.470 |
Why?
|
| Pulmonary Blastoma | 1 | 2015 | 12 | 0.460 |
Why?
|
| Aorta | 3 | 2021 | 550 | 0.450 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2014 | 14 | 0.440 |
Why?
|
| Ribonuclease III | 1 | 2015 | 99 | 0.440 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2011 | 240 | 0.440 |
Why?
|
| Presenilin-1 | 2 | 2020 | 57 | 0.430 |
Why?
|
| Lung | 4 | 2007 | 1559 | 0.430 |
Why?
|
| Computer Peripherals | 1 | 2013 | 4 | 0.420 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2015 | 146 | 0.420 |
Why?
|
| Cerebral Arteries | 1 | 2014 | 83 | 0.420 |
Why?
|
| Vascular Diseases | 1 | 2015 | 150 | 0.400 |
Why?
|
| Musculoskeletal Diseases | 1 | 2013 | 56 | 0.400 |
Why?
|
| Nanostructures | 4 | 2008 | 63 | 0.400 |
Why?
|
| Stroke | 1 | 2021 | 1085 | 0.390 |
Why?
|
| Chest Pain | 1 | 2013 | 128 | 0.390 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 228 | 0.370 |
Why?
|
| Delayed-Action Preparations | 3 | 2007 | 123 | 0.370 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 476 | 0.370 |
Why?
|
| Nanomedicine | 1 | 2012 | 26 | 0.360 |
Why?
|
| Boronic Acids | 1 | 2012 | 47 | 0.360 |
Why?
|
| Mice, Knockout | 4 | 2025 | 3861 | 0.360 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 313 | 0.350 |
Why?
|
| Amyloid beta-Peptides | 1 | 2012 | 226 | 0.340 |
Why?
|
| Coronary Angiography | 1 | 2013 | 485 | 0.340 |
Why?
|
| Pediatrics | 1 | 2020 | 1213 | 0.340 |
Why?
|
| Mice, Transgenic | 6 | 2022 | 2444 | 0.340 |
Why?
|
| Aortic Diseases | 1 | 2013 | 196 | 0.330 |
Why?
|
| Humans | 43 | 2025 | 132089 | 0.330 |
Why?
|
| Neuroimaging | 3 | 2021 | 377 | 0.330 |
Why?
|
| Rats | 13 | 2020 | 3609 | 0.320 |
Why?
|
| Models, Biological | 4 | 2011 | 1443 | 0.320 |
Why?
|
| Health Care Costs | 1 | 2013 | 414 | 0.320 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 1538 | 0.320 |
Why?
|
| Brain | 4 | 2024 | 3176 | 0.310 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 688 | 0.310 |
Why?
|
| Polyethylene Glycols | 6 | 2012 | 251 | 0.300 |
Why?
|
| Female | 24 | 2025 | 70695 | 0.290 |
Why?
|
| Particle Size | 6 | 2009 | 149 | 0.270 |
Why?
|
| Administration, Inhalation | 5 | 2007 | 190 | 0.270 |
Why?
|
| Iohexol | 2 | 2007 | 22 | 0.270 |
Why?
|
| Aerosols | 2 | 2007 | 64 | 0.260 |
Why?
|
| Glucose | 2 | 2012 | 870 | 0.250 |
Why?
|
| Pregnancy | 6 | 2025 | 7555 | 0.250 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 66 | 0.250 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2022 | 199 | 0.250 |
Why?
|
| Cardiology | 1 | 2012 | 498 | 0.250 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2017 | 1222 | 0.250 |
Why?
|
| Mice, Nude | 4 | 2018 | 751 | 0.250 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 450 | 0.240 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1170 | 0.230 |
Why?
|
| Ligands | 4 | 2021 | 494 | 0.230 |
Why?
|
| Child | 13 | 2025 | 25786 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3351 | 0.210 |
Why?
|
| Folic Acid | 2 | 2006 | 288 | 0.210 |
Why?
|
| Microspheres | 1 | 2003 | 72 | 0.210 |
Why?
|
| Tumor Burden | 4 | 2021 | 247 | 0.210 |
Why?
|
| Tomography, Spiral Computed | 1 | 2003 | 15 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2019 | 604 | 0.200 |
Why?
|
| Rheology | 1 | 2003 | 32 | 0.200 |
Why?
|
| Mouth Neoplasms | 2 | 2023 | 97 | 0.200 |
Why?
|
| Carrier Proteins | 2 | 2005 | 1047 | 0.190 |
Why?
|
| Bronchi | 1 | 2003 | 103 | 0.190 |
Why?
|
| Vimentin | 1 | 2022 | 67 | 0.190 |
Why?
|
| Adventitia | 1 | 2022 | 6 | 0.190 |
Why?
|
| Image Enhancement | 3 | 2008 | 172 | 0.180 |
Why?
|
| Antineoplastic Agents | 5 | 2011 | 1826 | 0.180 |
Why?
|
| Male | 18 | 2025 | 64967 | 0.180 |
Why?
|
| Trachea | 1 | 2003 | 210 | 0.180 |
Why?
|
| Protein Binding | 2 | 2018 | 1730 | 0.180 |
Why?
|
| Indans | 1 | 2021 | 54 | 0.180 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2023 | 153 | 0.170 |
Why?
|
| Moyamoya Disease | 1 | 2021 | 42 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 4754 | 0.170 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 212 | 0.170 |
Why?
|
| Disposable Equipment | 1 | 2020 | 18 | 0.170 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 1659 | 0.170 |
Why?
|
| Structure-Activity Relationship | 2 | 2021 | 588 | 0.170 |
Why?
|
| alpha-Synuclein | 1 | 2021 | 126 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2021 | 93 | 0.160 |
Why?
|
| Nanotechnology | 3 | 2009 | 50 | 0.160 |
Why?
|
| Nasopharynx | 1 | 2020 | 88 | 0.160 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 3681 | 0.160 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 161 | 0.160 |
Why?
|
| Finger Phalanges | 1 | 2019 | 3 | 0.160 |
Why?
|
| Age Determination by Skeleton | 1 | 2019 | 11 | 0.160 |
Why?
|
| Appendicitis | 1 | 2021 | 138 | 0.160 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 49 | 0.160 |
Why?
|
| tau Proteins | 1 | 2022 | 235 | 0.160 |
Why?
|
| Aortic Rupture | 1 | 2021 | 119 | 0.160 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 317 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2322 | 0.150 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 215 | 0.150 |
Why?
|
| Adult | 6 | 2025 | 31575 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 1672 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 2092 | 0.150 |
Why?
|
| Binding, Competitive | 2 | 2012 | 161 | 0.150 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2018 | 42 | 0.150 |
Why?
|
| Iodine | 2 | 2016 | 24 | 0.150 |
Why?
|
| Placentation | 1 | 2019 | 60 | 0.150 |
Why?
|
| Solubility | 1 | 2018 | 125 | 0.150 |
Why?
|
| Limit of Detection | 1 | 2018 | 77 | 0.150 |
Why?
|
| Infant | 5 | 2025 | 13061 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 385 | 0.140 |
Why?
|
| Child Abuse | 1 | 2021 | 204 | 0.140 |
Why?
|
| Molecular Conformation | 1 | 2018 | 106 | 0.140 |
Why?
|
| Disease Progression | 2 | 2021 | 2225 | 0.140 |
Why?
|
| Aortic Aneurysm | 1 | 2021 | 237 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2021 | 305 | 0.140 |
Why?
|
| Child, Preschool | 5 | 2025 | 14749 | 0.140 |
Why?
|
| Chickens | 1 | 2017 | 302 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 622 | 0.130 |
Why?
|
| Membranes, Artificial | 1 | 2017 | 29 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 767 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1444 | 0.130 |
Why?
|
| Models, Animal | 1 | 2019 | 469 | 0.130 |
Why?
|
| Chitosan | 1 | 2017 | 31 | 0.130 |
Why?
|
| Materials Testing | 1 | 2017 | 78 | 0.130 |
Why?
|
| Molecular Structure | 2 | 2021 | 322 | 0.130 |
Why?
|
| Doxorubicin | 3 | 2009 | 303 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2022 | 380 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2022 | 391 | 0.130 |
Why?
|
| Gadolinium DTPA | 2 | 2007 | 49 | 0.130 |
Why?
|
| Cattle | 1 | 2017 | 569 | 0.130 |
Why?
|
| Echo-Planar Imaging | 1 | 2016 | 23 | 0.120 |
Why?
|
| Rabbits | 3 | 2007 | 673 | 0.120 |
Why?
|
| Heterografts | 1 | 2016 | 197 | 0.120 |
Why?
|
| Hydrogels | 1 | 2017 | 108 | 0.120 |
Why?
|
| Pericardium | 1 | 2017 | 102 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 862 | 0.120 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 110 | 0.120 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2007 | 166 | 0.120 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 2140 | 0.120 |
Why?
|
| Time Factors | 6 | 2022 | 6448 | 0.120 |
Why?
|
| Organometallic Compounds | 2 | 2016 | 111 | 0.120 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2015 | 3 | 0.110 |
Why?
|
| Retinal Dehydrogenase | 1 | 2014 | 12 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2015 | 63 | 0.110 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 81 | 0.110 |
Why?
|
| Gestational Age | 1 | 2019 | 1224 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2015 | 146 | 0.110 |
Why?
|
| Models, Molecular | 1 | 2018 | 1117 | 0.110 |
Why?
|
| Whole Body Imaging | 2 | 2012 | 29 | 0.110 |
Why?
|
| Fanconi Anemia | 1 | 2014 | 39 | 0.110 |
Why?
|
| Drug Compounding | 2 | 2011 | 42 | 0.110 |
Why?
|
| Isoenzymes | 1 | 2014 | 223 | 0.110 |
Why?
|
| Biomarkers | 2 | 2022 | 3407 | 0.110 |
Why?
|
| Molecular Imaging | 2 | 2016 | 63 | 0.110 |
Why?
|
| Drug Design | 2 | 2021 | 161 | 0.100 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 84 | 0.100 |
Why?
|
| Retrospective Studies | 8 | 2023 | 17416 | 0.100 |
Why?
|
| Models, Economic | 1 | 2013 | 61 | 0.100 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1694 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2013 | 791 | 0.100 |
Why?
|
| Phosphatidylethanolamines | 1 | 2012 | 22 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 761 | 0.100 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2007 | 51 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2016 | 1046 | 0.100 |
Why?
|
| Fetus | 1 | 2016 | 588 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 462 | 0.100 |
Why?
|
| Triage | 1 | 2013 | 149 | 0.090 |
Why?
|
| Concanavalin A | 1 | 2012 | 15 | 0.090 |
Why?
|
| Uterus | 1 | 2016 | 548 | 0.090 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 200 | 0.090 |
Why?
|
| Administration, Intravenous | 1 | 2012 | 162 | 0.090 |
Why?
|
| Coordination Complexes | 1 | 2011 | 7 | 0.090 |
Why?
|
| Dextrans | 1 | 2012 | 47 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 310 | 0.090 |
Why?
|
| Myocardium | 1 | 2017 | 908 | 0.090 |
Why?
|
| Equipment Design | 1 | 2013 | 603 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2012 | 92 | 0.090 |
Why?
|
| Cell Survival | 2 | 2012 | 866 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 326 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 119 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 257 | 0.090 |
Why?
|
| Biological Transport | 1 | 2012 | 348 | 0.090 |
Why?
|
| Immunocompetence | 1 | 2011 | 32 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 36 | 0.090 |
Why?
|
| Mammography | 2 | 2009 | 132 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 1284 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2012 | 280 | 0.090 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 45 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 576 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 297 | 0.080 |
Why?
|
| Cell Line | 2 | 2013 | 2719 | 0.080 |
Why?
|
| HeLa Cells | 1 | 2012 | 731 | 0.080 |
Why?
|
| Residence Characteristics | 2 | 2023 | 286 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2013 | 824 | 0.080 |
Why?
|
| Pandemics | 3 | 2022 | 1183 | 0.080 |
Why?
|
| Surface Properties | 1 | 2009 | 93 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2012 | 455 | 0.080 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 480 | 0.080 |
Why?
|
| Capillary Permeability | 1 | 2009 | 73 | 0.080 |
Why?
|
| Macrophages | 1 | 2013 | 689 | 0.070 |
Why?
|
| Comorbidity | 1 | 2013 | 1611 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 333 | 0.070 |
Why?
|
| Lipids | 1 | 2012 | 561 | 0.070 |
Why?
|
| Folate Receptors, GPI-Anchored | 2 | 2005 | 54 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 1305 | 0.070 |
Why?
|
| Technology, Pharmaceutical | 1 | 2007 | 20 | 0.070 |
Why?
|
| Autophagy | 1 | 2011 | 426 | 0.070 |
Why?
|
| Hippocampus | 1 | 2012 | 816 | 0.070 |
Why?
|
| Capsules | 1 | 2007 | 22 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 131 | 0.060 |
Why?
|
| Adolescent | 5 | 2025 | 20560 | 0.060 |
Why?
|
| Risk Factors | 1 | 2021 | 10946 | 0.060 |
Why?
|
| Prevalence | 1 | 2013 | 2658 | 0.060 |
Why?
|
| Spine | 1 | 2007 | 147 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 120 | 0.060 |
Why?
|
| Aged | 3 | 2025 | 21438 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 207 | 0.060 |
Why?
|
| Urethane | 1 | 2004 | 6 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3629 | 0.060 |
Why?
|
| Photons | 1 | 2025 | 53 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 189 | 0.050 |
Why?
|
| Genome, Viral | 1 | 2025 | 179 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 270 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2013 | 3739 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2025 | 327 | 0.050 |
Why?
|
| Respiratory Transport | 1 | 2003 | 2 | 0.050 |
Why?
|
| Bronchography | 1 | 2003 | 6 | 0.050 |
Why?
|
| Drug Stability | 1 | 2003 | 59 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2025 | 205 | 0.050 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2003 | 20 | 0.050 |
Why?
|
| Pulmonary Ventilation | 1 | 2003 | 31 | 0.050 |
Why?
|
| Radiography, Abdominal | 1 | 2003 | 49 | 0.050 |
Why?
|
| Finite Element Analysis | 1 | 2003 | 35 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 67 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 1900 | 0.050 |
Why?
|
| Cadaver | 1 | 2003 | 119 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 3011 | 0.050 |
Why?
|
| Middle Aged | 3 | 2025 | 28998 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 308 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2006 | 1121 | 0.050 |
Why?
|
| Protein Aggregates | 1 | 2021 | 31 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2023 | 263 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 75 | 0.040 |
Why?
|
| Radiometry | 1 | 2021 | 43 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2012 | 174 | 0.040 |
Why?
|
| Policy | 1 | 2021 | 37 | 0.040 |
Why?
|
| Potassium | 1 | 2022 | 275 | 0.040 |
Why?
|
| Mutation | 1 | 2015 | 6228 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 89 | 0.040 |
Why?
|
| Sodium | 1 | 2022 | 295 | 0.040 |
Why?
|
| Protein Folding | 1 | 2021 | 223 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2021 | 55 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 88 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 257 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2021 | 74 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 195 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2021 | 163 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 380 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 990 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 105 | 0.040 |
Why?
|
| Blood Volume | 1 | 2019 | 80 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 1378 | 0.040 |
Why?
|
| Body Composition | 1 | 2022 | 550 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2021 | 255 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 624 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 523 | 0.040 |
Why?
|
| Logistic Models | 1 | 2023 | 1839 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 852 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 348 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2025 | 1828 | 0.030 |
Why?
|
| Machine Learning | 1 | 2021 | 346 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 1997 | 24 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 568 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1997 | 55 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2025 | 3092 | 0.030 |
Why?
|
| Polyesters | 1 | 2017 | 41 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2021 | 988 | 0.030 |
Why?
|
| Meglumine | 1 | 2016 | 16 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2020 | 800 | 0.030 |
Why?
|
| Critical Care | 1 | 2022 | 686 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 82 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 66 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2022 | 1697 | 0.030 |
Why?
|
| Cell Death | 2 | 2008 | 241 | 0.030 |
Why?
|
| United States | 2 | 2021 | 11667 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 1035 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 27 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 42 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1722 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 800 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 199 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2011 | 3037 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 347 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 38 | 0.020 |
Why?
|
| Hydrodynamics | 1 | 2011 | 28 | 0.020 |
Why?
|
| Amides | 1 | 2011 | 91 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 575 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2011 | 30 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 57 | 0.020 |
Why?
|
| Young Adult | 1 | 2025 | 9958 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 451 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 100 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 138 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 1028 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 169 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2009 | 18 | 0.020 |
Why?
|
| X-Rays | 1 | 2009 | 31 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 62 | 0.020 |
Why?
|
| Proteins | 1 | 2014 | 1035 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 227 | 0.020 |
Why?
|
| Phospholipids | 1 | 2009 | 104 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 102 | 0.020 |
Why?
|
| Carcinoma | 1 | 2011 | 299 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 876 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2009 | 138 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 719 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2007 | 34 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 763 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2011 | 527 | 0.020 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2007 | 7 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 795 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1952 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 2007 | 19 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1011 | 0.020 |
Why?
|
| Blood | 1 | 2007 | 102 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 2057 | 0.020 |
Why?
|
| KB Cells | 1 | 2006 | 5 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 97 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 444 | 0.020 |
Why?
|
| Veins | 1 | 2007 | 104 | 0.020 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 36 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2006 | 94 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 105 | 0.020 |
Why?
|
| Artifacts | 1 | 2007 | 114 | 0.020 |
Why?
|
| Arteries | 1 | 2007 | 222 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2008 | 1573 | 0.010 |
Why?
|
| Glioma | 1 | 2009 | 529 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 1892 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2003 | 120 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2508 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 457 | 0.010 |
Why?
|
| Computational Biology | 1 | 2007 | 875 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 4528 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 13034 | 0.010 |
Why?
|
| Prognosis | 1 | 2008 | 5014 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2648 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 4704 | 0.010 |
Why?
|
| Culture Media | 1 | 1997 | 183 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 216 | 0.010 |
Why?
|
| Perfusion | 1 | 1997 | 208 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 822 | 0.010 |
Why?
|